课题基金 / 基金详情

Role of Parkin in Familial and Idiopathic Parkinson's Disease

Role of Parkin in Familial and Idiopathic Parkinson's Disease
Parkin 在家族性和特发性帕金森病中的作用
批准号:
7984298
负责人:
Matthew J Lavoie
金额:
$38.43万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-01 至 2015-04-30

项目摘要

项目成果

Matthew J Lavoie的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):帕金森病(PD)是一种进行性神经退行性疾病,其特征是黑质中神经元的近选择性丧失。虽然该疾病的病因尚不清楚,但导致家族性帕金森病的基因突变可能会为特发性疾病的潜在机制提供关键的分子线索。泛素 E3 连接酶 Parkin 的功能丧失突变是常染色体隐性遗传 PD 的最常见原因。 Parkin 现在被广泛认为是一种在细胞损伤过程中快速上调的促生存蛋白。 Parkin 被认为对线粒体生物学具有广泛的影响,这可能与特发性 PD 相关。然而,这些效应的生化底物在很大程度上是未知的。我们工作的长期目标是揭示帕金对线粒体影响的分子机制。这些信息不仅将提高我们对重要神经元应激反应蛋白的理解,还将阐明可能参与帕金森病选择性神经变性的新生化途径。该应用的实验重点是由于神经元 Parkin 缺陷而导致的线粒体缺陷,并确定相关蛋白质。具体目标有三个。 1) 分析参与线粒体裂变和凋亡的两种新型parkin底物的parkin依赖性泛素化。我们将确定内源性 Parkin 对蛋白质半衰期和定位的影响,以及这些候选底物对 Parkin 缺陷神经元线粒体缺陷的贡献。 2) 分析原代培养神经元中 Parkin 缺陷的线粒体后果,并检查 Parkin 缺失神经元对特发性 PD 相关应激源的脆弱性增强。 3) 检查 Parkin 缺陷神经元中发生的蛋白质运输和功能的线粒体特异性变化。这些研究的完成将在 Parkin 的 E3 连接酶活性与其作为具有线粒体影响的促生存应激反应蛋白的功能之间建立机制联系。这项工作将阐明帕金森病发病机制中涉及的新生化途径,并有可能发现治疗干预的创新靶点。 公众健康相关性:帕金蛋白与保护性神经元应激反应密切相关,并且与家族性帕金森病存在因果关系。这项研究的目的是了解帕金维持线粒体完整性的精确机制,并确定可能导致帕金森病的分子事件。这些途径一旦被发现,可能会确定治疗这种破坏性神经系统疾病的新治疗靶点。
英文摘要
DESCRIPTION (provided by applicant): Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the near selective loss of neurons in the substantia nigra. While the etiology of the disease is unknown, genetic mutations responsible for familial forms of PD will likely provide critical molecular clues to the underlying mechanisms of idiopathic disease. Loss-of-function mutations in the ubiquitin E3 ligase parkin are the most common cause of autosomal recessive PD. Parkin is now widely recognized as a pro-survival protein rapidly up-regulated during cell injury. Parkin is believed to possess broad ranging effects on mitochondrial biology that are likely relevant to idiopathic PD. However, the biochemical substrates of these effects are largely unknown. The long-term goal of our work is to uncover the molecular machinery responsible for parkin's influence on mitochondria. This information will not only improve our understanding of an important neuronal stress response protein but will also elucidate new biochemical pathways likely involved in the selective neurodegeneration in PD. The experimental focus of this application is on the mitochondrial defects that result from neuronal deficiencies in parkin and identifying the proteins responsible. There are three specific aims. 1) Analyze the parkin-dependent ubiquitination of two novel parkin substrates involved in mitochondrial fission and apoptosis. We will determine the effects of endogenous parkin on protein half-life and localization, and the contribution of these candidate substrates on mitochondrial defects in parkin deficient neurons. 2) Analyze the mitochondrial consequences of parkin deficiency in primary cultured neurons, and examine enhanced vulnerabilities of parkin null neurons to stressors implicated in idiopathic PD. 3) Examine mitochondria-specific changes in protein trafficking and function that occur in parkin deficient neurons. The completion of these studies will establish mechanistic links between the E3 ligase activity of parkin and its function as a pro-survival stress response protein with mitochondrial influence. This work will elucidate novel biochemical pathways involved in the pathogenesis of PD and potentially uncover innovative targets for therapeutic intervention. PUBLIC HEALTH RELEVANCE: Parkin is critically involved in a protective neuronal stress response and is causally linked to familial Parkinson's disease. The goal of this study is to understand the precise mechanisms by which parkin maintains integrity of the mitochondria and to define molecular events that can cause Parkinson's disease. These pathways, once discovered, may identify new therapeutic targets for the treatment of this devastating neurological disorder.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pathologic LRRK2 signaling in Familial and Idiopathic Parkinson's Disease
  • 批准号:
    9791022
  • 项目类别:
  • 资助金额:
    $45.02万
  • 财政年份:
    2018
  • 负责人:
    Matthew J Lavoie
  • 依托单位:
PATHOLOGIC LRRK2 SIGNALING IN FAMILIAL AND IDIOPATHIC PARKINSON'S DISEASE
  • 批准号:
    10241552
  • 项目类别:
  • 资助金额:
    $35.12万
  • 财政年份:
    2018
  • 负责人:
    Matthew J Lavoie
  • 依托单位:
PATHOLOGIC LRRK2 SIGNALING IN FAMILIAL AND IDIOPATHIC PARKINSON'S DISEASE
  • 批准号:
    10459599
  • 项目类别:
  • 资助金额:
    $35.12万
  • 财政年份:
    2018
  • 负责人:
    Matthew J Lavoie
  • 依托单位:
The Activation of LRRK2 by Alpha-Synuclein
  • 批准号:
    8925936
  • 项目类别:
  • 资助金额:
    $26.0万
  • 财政年份:
    2014
  • 负责人:
    Matthew J Lavoie
  • 依托单位:
海外基金